Answers are grounded in this paper and cite their sources.
Kidney transplant recipients with complement-dependent cytotoxicity (CDC) B-cell or flow-cytometry (FC) T/B crossmatch positivity are at higher risk for the development of acute and chronic rejection, and decreased graft survival due to anti-HLA donor-specific antibodies (DSA) (1, 2). Intravenous immunoglobulin (IVIG) has immunomodulatory effects and has been shown to facilitate kidney transplantation in crossmatch positive patients by downregulating anti-HLA DSAs (3). We have recently reported our experience with IVIG and thymoglobulin induction treatment in eight CDC and FC B-cell crossmatch positive kidney transplant recipients (four also had FC T-cell crossmatch positivity) (4). Only one patient with pretransplant class I anti-HLA DSAs had early acute antibody mediated humoral rejection, and none developed acute cellular rejection. After those eight patients, we treated an additional seven immunologically high-risk living-donor kidney transplant recipients (five female, two male; four white, two Hispanic, one black; three second-transplant recipients) with low dose IVIG (100 mg/kg for 3 days) and thymoglobulin (1.5 mg/kg for 5 days) induction. Five patients received maintenance immunosuppression with cyclosporin microemulsion and two patients received tacrolimus along with mycophenolate mofetil and prednisone. Five patients had FC T- and B-cell (one also had CDC B-cell) and two patients had CDC and FC B-cell crossmatch positivity. Three patients had both anti-HLA class I and II, one patient had class I, and one patients had class II DSAs, as determined by Flow Beads (Luminex). Two patients did not have demonstrated pretransplant DSAs. Two patients developed early acute humoral rejection with positive C4d staining; both had positive FC T- and B-cell crossmatch with anti-class I and II DSAs. One patient with borderline acute rejection responded to IVIG treatment and has stable renal function with a creatinine level of 1.5 mg/dl. However, the other patient with severe acute humoral rejection did not respond to IVIG treatment along with plasmapheresis and rituximab, and eventually underwent transplant nephrectomy. The remaining five patients have stable renal function with a creatinine levels between 0.8–1.0 mg/dl at median 16 months follow-up, range 6–34 months. The patient’s DSAs were studied at 6–12 months after transplantation by Flow Beads. When we evaluated all 15 patients receiving IVIG and thymoglobulin induction treatment, four patients lost pretransplant class II and two patients lost class I DSAs after transplantation. However, four patients developed de novo DSAs. These results indicate that low-dose IVIG and thymoglobulin induction treatment has immunomodulatory effects by downregulating preformed DSAs, but does not prevent the development of de novo DSAs. The immunomodulatory effects of IVIG treatment persist beyond its half-life, indicating ongoing active inhibitory mechanisms and/or induction of neutralizing antiidiotypic antibodies. Three out of five patients with pretransplant class I DSAs developed early acute antibody-mediated humoral rejection, indicating the importance of preformed class I DSAs in humoral rejection, and lack of adequacy in preventing this event with our current protocol. In view of this, we now use higher doses of IVIG (300–500 mg/kg) treatment in patients with pretransplant class I DSAs. The effects of increasing the doses of IVIG on the development of acute rejection, DSA titers, and graft survival requires further follow-up. Enver Akalin Scott Ames Vinita Sehgal Barbara Murphy Jonathan S. Bromberg Department of Nephrology Recanati/Miller Transplantation Institute Mount Sinai Medical Center New York, NY Marilena Fotino Rex Friedlander Rogosin Immunogenetics Laboratory New York, NY
No takes yet. Share an insight, caveat, or question.
Akalin et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: